Pluri Inc. (NASDAQ: PLUR)

Pluri Inc., a biotechnology company with the ticker symbol PLUR, operates in the field of allogeneic placenta-based cell therapy products. The company's primary business activities involve the research, development, and manufacturing of cells and cell-based products, conducting clinical studies, and business development of cell therapeutics and cell-based technologies. Pluri's technology platform is based on a patented and validated 3D cell expansion system that utilizes a synthetic scaffold to create an artificial 3D environment where cells can grow.

Pluri's main business activities revolve around the research, development, and manufacturing of cells and cell-based products, conducting clinical studies, and business development of cell therapeutics and cell-based technologies. The company's technology platform is based on a patented and validated 3D cell expansion system that utilizes a synthetic scaffold to create an artificial 3D environment where cells can grow. Pluri's operations span across various countries and regions, with its headquarters in the United States and a significant presence in the food tech sector through its new venture, Ever After Foods Ltd. in Israel.

Pluri generates revenue through the development and commercialization of its cell therapy products, including PLX-PAD, PLX-R18, and modified PLX cells. PLX-PAD is a placenta-based cell therapy product candidate being developed for the treatment of inflammatory, muscle injuries, and hematologic conditions. PLX-R18 is a placenta-based cell therapy product candidate being developed for the treatment of radiation syndrome and other indications. The company's primary customers include various pharmaceutical companies, research institutions, and food tech companies.

In terms of its competitive position, Pluri is a leader in the regenerative medicine and food tech industries, with a strong pipeline of product candidates and a significant intellectual property portfolio. The company's competitors include other biotechnology companies that are developing similar cell-based products and technologies. Pluri's competitive advantages include its patented and validated 3D cell expansion system, its strong intellectual property portfolio, and its in-house manufacturing capabilities.

Pluri's manufacturing process is designed to ensure the quality and consistency of its products, and it has developed a serum-free formulation to support the manufacturing of its cell therapy products. The company is committed to maintaining its intellectual property and ensuring compliance with regulatory requirements. Pluri's products are subject to regulation as biological products under the Public Health Service Act and the Federal Food, Drug and Cosmetic Act in the United States, as well as by the European Medicines Agency and other regulatory authorities in the European Union.

In the food tech sector, Pluri's cultivated meat products are subject to regulation by various government agencies, including the FDA, USDA, and the U.S. Federal Trade Commission. The company's customers are expected to face regulatory requirements related to food quality and safety, labeling, and marketing and advertising to consumers. Pluri's competitors in the cultivated meat domain include both producers of consumer-end-products, as well as those developing inputs for the production process. Ever After Foods competes with companies such as Upside Foods, Believer Meats, GOOD Meat, Mosa Meat, Aleph Farms, Stakeholder 3D, and Gourmey.

Pluri's ability to compete successfully depends on its continued ability to attract and retain experienced and skilled executives and scientific and clinical development personnel, identify and develop viable cellular therapeutic candidates, exploit these products commercially, and keep expanding and improving its unique technological capabilities. As of June 30, 2023, Pluri employed a total of 123 full-time employees and 11 part-time employees, of whom 97 full-time employees and 9 part-time employees are engaged in cell research, development, and manufacturing, including clinical and regulation affairs, excluding Ever After Foods.